The black box warning for topical calcineurin inhibitors: looking outside the box.
Fonacier
Luz
L
Winthrop University Hospital, State University of New York, Stony Brook School of Medicine, New York, USA.
Charlesworth
Ernest N
EN
Spergel
Jonathan M
JM
Leung
Donald Y M
DY
D000287:Administration, Topical; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000486:Allergy and Immunology; D001291:Attitude of Health Personnel; D001294:Attitude to Health; D015984:Causality; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy; D004348:Drug Labeling; D005239:Fear; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced / Q000453:epidemiology; D008232:Lymphoproliferative Disorders / Q000139:chemically induced; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D010342:Patient Acceptance of Health Care; D010361:Patients / Q000523:psychology; D010820:Physicians / Q000523:psychology; D011788:Quality of Life; D012878:Skin Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D012955:Societies, Medical; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
C117268:pimecrolimus; D016559:Tacrolimus